PROCESS LIFECYCLE VALIDATION - Risk Management Applications in Pharmaceutical and Biopharmaceutical Manufacturing - page 219

9. Mollah AH. Risk Analysis and Process Validation. Bioprocess International, oct
2004;2(9):28-35.
10. Mollah AH. Application of FMEA for Process Risk Assessment. Bioprocess Interna-
tional; Nov 2005;3(10):12-20.
11. Q9, Quality Risk Management, ICH Harmonised Tripartite Guideline, Nov 2005.
12. Validation by Design: The Statistical Handbook for Pharmaceutical Process Valida-
tion, Lynn D. Torbeck, Co-Published PDA Books, 2010.
13. Wang X, Germansderfer A, Harms J, Rathore AS. Using statistical analysis for
setting process validation acceptance criteria for biotech products. Biotech Prog
2007;23:55-60.
14. Q7, Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, ICH
Harmonised Tripartite Guideline, November 2000.
15. Boven K, Stryker S, et al. The increased incidence of pure red cell apla-
sia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int
2005;67:2346-2353.
16. Process Validation of Protein Manufacturing, PDA Technical Report No. 42, 2005.
17. Q10, Pharmaceutical Quality System, ICH Harmonised Tripartite Guideline, June
2008.
18. Amit Banerjee, Designing in quality: approaches to defining the design space for
a monoclonal antibody process: how to use risk assessment strategies to integrate
operations, BioPharm Int, May 2010;23(5):26-40.
19. Steven Walfish and Thomas Harrington, Practical Application of Design of Experi-
ments in Biopharmaceutical Process Characterization, IBC's 2009 Process Validation,
March 2009.
20. EMEA/CVMP/598/99, Note for Guidance on Process Validation (March 2001)
CPMP/QWP/848/96.
21. Tran, N.L., Hasselbalch, B., et al., Elicitation of expert knowledge about risks
associated with pharmaceutical manufacturing processes, Pharm Eng, 25(4):24-38,
July/Aug 2005.
22. Ganzer WP, Materna JA, et al. Current Thoughts on Critical Process Parame-
ters and API Synthesis. Pharm Technol; July 2005. http://www.pharmtech.com/
pharmtech/article/articleDetail.jsp?id=170114.
23. Potter, C., PQLI application of science- and risk-based approaches (ICH Q8, Q9, and
Q10) to existing products, J. Pharm Innovation; 4:4-23, March 2009.
24. PQRI Workgroup Members, Process robustness—a PQRI white paper, PQRI working
group, Pharm Eng, Nov/Dec 2006, vol 26, No. 6. Exclusive On-line article, p.1-11.
25. Hospira warning letter by FDA, 12 April 2010 (http://www.fda.gov/ICECI/
EnforcementActions/WarningLetters/ucm208691.htm).
26. Louis Johnson and and Sarah Burrows, For Starbucks, It's in the Bag: How the
Java Giant Fine-Tuned its Sealing Process and Improved Product Quality, Quality
Progress, p. 19-23, March 2011.
27. PIC/S Guide to Validation Master Plan, Installation and Operational Qualification,
Non-Sterile Process Validation and Cleaning Validation, 25 September 2007.
28. Brian Hasselbalch, FDA at the PDA/FDA Workshop Oct 26, 2009, Bethesda, Mary-
land, Presentation “Process Validation: A Lifecycle Approach” and Q&A on Stage
2- Performance qualification.